Thomas C Case
Overview
Explore the profile of Thomas C Case including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Case T, Merkel A, Ramirez-Solano M, Liu Q, Sterling J, Jin R
Transl Oncol
. 2021 Aug;
14(11):101213.
PMID: 34461557
Clinical management of castration-resistant prostate cancer (CRPC) resulting from androgen deprivation therapy (ADT) remains challenging. Many studies indicate that androgen receptor splice variants (ARVs) play a critical role in the...
2.
Kohrt S, Awadallah W, Phillips 3rd R, Case T, Jin R, Nanda J, et al.
Mol Cancer Ther
. 2020 Dec;
20(2):398-409.
PMID: 33298586
Castration-resistant prostate cancer can be treated with the antiandrogen enzalutamide, but responses and duration of response are variable. To identify genes that support enzalutamide resistance, we performed a short hairpin...
3.
Popovics P, Awadallah W, Kohrt S, Case T, Miller N, Ricke E, et al.
Prostate
. 2020 May;
80(10):731-741.
PMID: 32356572
Background: Male lower urinary tract symptoms (LUTS) occur in more than half of men above 50 years of age. LUTS were traditionally attributed to benign prostatic hyperplasia (BPH) and therefore...
4.
Qiao J, Grabowska M, Forestier-Roman I, Mirosevich J, Case T, Chung D, et al.
Oncotarget
. 2016 Aug;
7(38):61955-61969.
PMID: 27542219
Numerous studies indicate that androgen receptor splice variants (ARVs) play a critical role in the development of castration-resistant prostate cancer (CRPC), including the resistance to the new generation of inhibitors...
5.
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann B, Strand D, et al.
Mol Oncol
. 2013 Aug;
7(6):1019-30.
PMID: 23916135
Purpose: Metastasis, the main cause of death from cancer, remains poorly understood at the molecular level. Experimental Design: Based on a pattern of reduced expression in human prostate cancer tissues...
6.
Lu J, Zhang J, Kim K, Case T, Matusik R, Chen Y, et al.
Mol Cancer
. 2010 Nov;
9:304.
PMID: 21106062
Background: Neuronal synaptic junction protein δ-catenin (CTNND2) is often overexpressed in prostatic adenocarcinomas but the mechanisms of its activation are unknown. To address this question, we studied the hypothesis that...
7.
Zhang J, Gao N, DeGraff D, Yu X, Sun Q, Case T, et al.
Prostate
. 2010 Mar;
70(9):934-51.
PMID: 20209642
Background: The androgen-regulated probasin (PB) promoter has been used extensively to target transgenes to the prostate in transgenic mice; however, limited data exist on the mechanism that dictates prostate-specific gene...
8.
Jin R, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, et al.
Cancer Res
. 2008 Aug;
68(16):6762-9.
PMID: 18701501
Typically, the initial response of a prostate cancer patient to androgen ablation therapy is regression of the disease. However, the tumor will progress to an "androgen-independent" stage that results in...
9.
Matusik R, Jin R, Sun Q, Wang Y, Yu X, Gupta A, et al.
Differentiation
. 2008 May;
76(6):682-98.
PMID: 18462434
Androgen receptor (AR) within prostatic mesenchymal cells, with the absence of AR in the epithelium, is still sufficient to induce prostate development. AR in the luminal epithelium is required to...
10.
Gao N, Zhang J, Rao M, Case T, Mirosevich J, Wang Y, et al.
Mol Endocrinol
. 2003 May;
17(8):1484-507.
PMID: 12750453
Androgens and mesenchymal factors are essential extracellular signals for the development as well as the functional activity of the prostate epithelium. Little is known of the intraepithelial determinants that are...